Welcome to our dedicated page for Neuroone Med Technologies SEC filings (Ticker: NMTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a medical technology issuer focused on minimally invasive, high-definition EEG, ablation, drug delivery and brain stimulation solutions for neurological disorders, NeuroOne uses its SEC reports to present detailed information on its financial condition, operations, risks and material events.
Here you can review NeuroOne’s current reports on Form 8-K, which the company uses to announce events such as quarterly and annual financial results, preliminary revenue figures, FDA 510(k) clearances for devices like the OneRF Trigeminal Nerve Ablation System, capital raising activities and notices related to Nasdaq listing requirements. These filings often incorporate or reference press releases that describe product performance, regulatory milestones and developments in programs including the OneRF Ablation System, spinal cord stimulation initiatives and sEEG-based drug delivery.
In addition to 8-Ks, investors can consult NeuroOne’s periodic reports on Forms 10-Q and 10-K (when available) for comprehensive financial statements, management’s discussion and analysis, and risk factor disclosures tied to its neuromodulation and surgical appliance business. The company has also filed updates related to its at-the-market offering program, distribution agreements and other capital markets activities, which are documented in its SEC submissions.
Stock Titan enhances these NMTC filings with AI-powered summaries that highlight key points, such as revenue trends, gross margin changes, cash position commentary, regulatory updates and listing compliance discussions. Users can quickly identify items like FDA clearance announcements, preliminary annual revenue disclosures and Nasdaq minimum bid price notices, then drill into the full documents for deeper analysis. This page is designed to help investors, analysts and other interested readers efficiently navigate NeuroOne’s official SEC record.
NeuroOne Medical Technologies Corporation is enacting a 1-for-6 reverse stock split of its common stock. Every 6 existing shares will be reclassified into 1 new share, with no change to the total number of authorized shares or the $0.001 par value.
The split becomes effective at 5:00 p.m. Eastern Time on April 15, 2026, and NeuroOne’s stock will begin trading on a split-adjusted basis on April 16, 2026 under the symbol NMTC. Fractional share positions will not be issued; instead, affected stockholders will receive a cash payment equal to the market value of the fractional share. Equity incentive plan awards, options and warrants will be proportionally adjusted, and the company notes the reverse split may help it regain compliance with Nasdaq’s minimum bid price requirement.
NEUROONE MEDICAL TECHNOLOGIES Corp director Jason Richard Mills reported equity compensation awards. He received options to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments.
He also received a grant of 41,929 restricted stock units that vest in 12 equal monthly installments over one year, with vesting at the end of each month. Following the stock grant, he holds 49,687 shares of common stock directly.
NEUROONE MEDICAL TECHNOLOGIES Corp director Jeffrey S. Mathiesen received new equity compensation. On April 3, 2026, he was granted options to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036. These options vest in 12 equal monthly installments over one year.
On the same date, he also received 41,929 restricted stock units, which vest in 12 equal monthly installments over one year at the end of each month. Following these grants, he directly owns 156,343 shares of common stock. Both grants are compensation awards rather than open-market purchases.
NeuroOne Medical Technologies director Paul Buckman received new equity awards as compensation. He was granted an option to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments over one year.
He was also granted 41,929 restricted stock units that vest in 12 equal monthly installments over the same one-year period, with vesting at the end of each month. Following these awards, he directly holds 178,733 shares of common stock. These are grants, not open-market purchases.
NeuroOne Medical Technologies board member Edward Andrle reported receiving new equity awards. He was granted an option to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments over one year.
He also received 41,929 restricted stock units that vest in 12 equal monthly installments over the same one-year period, with vesting at each month-end. Following the stock grant, Andrle directly holds 133,932 shares of common stock.
NeuroOne Medical Technologies Corporation held its annual stockholder meeting and approved several key proposals, including a potential reverse stock split and changes to its equity incentive plan. Stockholders authorized the Board to implement a reverse stock split in a range from 1-for-2 to 1-for-15 of the outstanding common stock.
Two Class III directors, Jeffrey Mathiesen and Edward Andrle, were elected to three-year terms ending at the 2029 annual meeting. Stockholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, and approved an amendment to the 2025 Equity Incentive Plan. A total of 30,272,834 shares, representing approximately 59.72% of shares outstanding as of the record date, were present in person or by proxy.
NeuroOne Medical Technologies officer Mark Christianson reported recent transactions in the company’s Common Stock. On March 30, he completed an open-market sale of 15,363 shares at $0.74 per share. On March 31, an additional 253 shares were disposed of as a tax-withholding transaction, covering tax obligations rather than representing a market trade.
Following these transactions, Christianson holds 198,667 shares of NeuroOne Common Stock directly, according to the filing. The activity reflects a net reduction in his position, primarily driven by the open-market sale, with the smaller tax-withholding disposition tied to equity-related compensation.
NEUROONE MEDICAL TECHNOLOGIES Corp Chief Technology Officer Steve Mertens reported a small share disposition related to taxes, not an open-market trade. On this Form 4, 906 shares of common stock were withheld at $0.777 per share to satisfy a tax obligation. Following this tax-withholding disposition, Mertens directly holds 152,141 shares of common stock.
NEUROONE MEDICAL TECHNOLOGIES Corp director and CEO David A. Rosa reported a tax-related share disposition. On the reported date, 2,458 shares of Common Stock were delivered at $0.777 per share as a tax-withholding disposition to cover exercise price or tax liabilities. After this non-market transaction, he directly owned 1,080,132 shares of Common Stock.
NEUROONE MEDICAL TECHNOLOGIES Corp executive Mark Christianson, Business Development Director, reported small open-market sales of company common stock. He sold 817 shares on March 12, 2026 and 100 shares on March 13, 2026, both at $0.80 per share. After these transactions, he directly holds 214,283 shares of NeuroOne common stock.